source
- Nonprofits launch ultra-rare immune disease gene therapy Waskyra at $3.25 million priceTwo nonprofit organizations have received FDA approval for a gene therapy that targets an ultra-rare immune disorder. The therapy, called Waskyra, is now being launched with a list price of $3.25…
- AstraZeneca invests $2 billion for stake in Summit Therapeutics to back its cancer drugAstraZeneca announced on Monday that it will invest $2 billion to acquire a minority equity stake in Summit Therapeutics. The investment gives AstraZeneca a slice of the biotech as the companies mo…